Ablation of the TGF-β receptor I (ALK5) restores CXCR3 expression, enhances T cell infiltration and cytotoxicity, and promotes tumor regression, these effects are partially reversed by CXCR3 blockade. Here, CXCR3 is linked to neoplasm.